Cargando…
Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension
INTRODUCTION: Ravulizumab demonstrated efficacy and an acceptable safety profile versus placebo in the randomized controlled period (RCP) of the phase 3 CHAMPION MG trial in patients with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. We report an interim analysis of th...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134722/ https://www.ncbi.nlm.nih.gov/pubmed/37103755 http://dx.doi.org/10.1007/s00415-023-11699-x |
_version_ | 1785031819229396992 |
---|---|
author | Meisel, Andreas Annane, Djillali Vu, Tuan Mantegazza, Renato Katsuno, Masahisa Aguzzi, Rasha Frick, Glen Gault, Laura Howard, James F. |
author_facet | Meisel, Andreas Annane, Djillali Vu, Tuan Mantegazza, Renato Katsuno, Masahisa Aguzzi, Rasha Frick, Glen Gault, Laura Howard, James F. |
author_sort | Meisel, Andreas |
collection | PubMed |
description | INTRODUCTION: Ravulizumab demonstrated efficacy and an acceptable safety profile versus placebo in the randomized controlled period (RCP) of the phase 3 CHAMPION MG trial in patients with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. We report an interim analysis of the ongoing open-label extension (OLE) designed to evaluate long-term treatment effects. METHODS: Following completion of the 26-week RCP, patients could enter the OLE; patients who received ravulizumab in the RCP continued the drug; patients who previously received placebo switched to ravulizumab. Patients receive body-weight-based maintenance dosing of ravulizumab every 8 weeks. Efficacy endpoints up to 60 weeks included Myasthenia Gravis–Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scores, with least-squares (LS) mean change and 95% confidence intervals (95% CI) reported. RESULTS: Long-term efficacy and safety in the OLE were analyzed in 161 and 169 patients, respectively. Improvements in all scores were maintained through 60 weeks in patients who received ravulizumab during the RCP; LS mean change from RCP baseline in MG-ADL score was − 4.0 (95% CI: − 4.8, − 3.1; p < 0.0001). Rapid (within 2 weeks) and sustained improvements occurred in patients previously receiving placebo; LS mean change in MG-ADL score from OLE baseline to Week 60 was − 1.7 (95% CI: − 2.7, − 0.8; p = 0.0007). Similar trends were seen in QMG scores. Ravulizumab treatment was associated with a decreased rate of clinical deterioration events compared with placebo. Ravulizumab was well tolerated; no meningococcal infections were reported. CONCLUSION: Findings support the sustained efficacy and long-term safety of ravulizumab, administered every 8 weeks, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. ClinicalTrials.gov identifier: NCT03920293; EudraCT: 2018-003243-39. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00415-023-11699-x. |
format | Online Article Text |
id | pubmed-10134722 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-101347222023-04-28 Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension Meisel, Andreas Annane, Djillali Vu, Tuan Mantegazza, Renato Katsuno, Masahisa Aguzzi, Rasha Frick, Glen Gault, Laura Howard, James F. J Neurol Original Communication INTRODUCTION: Ravulizumab demonstrated efficacy and an acceptable safety profile versus placebo in the randomized controlled period (RCP) of the phase 3 CHAMPION MG trial in patients with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. We report an interim analysis of the ongoing open-label extension (OLE) designed to evaluate long-term treatment effects. METHODS: Following completion of the 26-week RCP, patients could enter the OLE; patients who received ravulizumab in the RCP continued the drug; patients who previously received placebo switched to ravulizumab. Patients receive body-weight-based maintenance dosing of ravulizumab every 8 weeks. Efficacy endpoints up to 60 weeks included Myasthenia Gravis–Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scores, with least-squares (LS) mean change and 95% confidence intervals (95% CI) reported. RESULTS: Long-term efficacy and safety in the OLE were analyzed in 161 and 169 patients, respectively. Improvements in all scores were maintained through 60 weeks in patients who received ravulizumab during the RCP; LS mean change from RCP baseline in MG-ADL score was − 4.0 (95% CI: − 4.8, − 3.1; p < 0.0001). Rapid (within 2 weeks) and sustained improvements occurred in patients previously receiving placebo; LS mean change in MG-ADL score from OLE baseline to Week 60 was − 1.7 (95% CI: − 2.7, − 0.8; p = 0.0007). Similar trends were seen in QMG scores. Ravulizumab treatment was associated with a decreased rate of clinical deterioration events compared with placebo. Ravulizumab was well tolerated; no meningococcal infections were reported. CONCLUSION: Findings support the sustained efficacy and long-term safety of ravulizumab, administered every 8 weeks, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. ClinicalTrials.gov identifier: NCT03920293; EudraCT: 2018-003243-39. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00415-023-11699-x. Springer Berlin Heidelberg 2023-04-27 2023 /pmc/articles/PMC10134722/ /pubmed/37103755 http://dx.doi.org/10.1007/s00415-023-11699-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Communication Meisel, Andreas Annane, Djillali Vu, Tuan Mantegazza, Renato Katsuno, Masahisa Aguzzi, Rasha Frick, Glen Gault, Laura Howard, James F. Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension |
title | Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension |
title_full | Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension |
title_fullStr | Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension |
title_full_unstemmed | Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension |
title_short | Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension |
title_sort | long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 champion mg open-label extension |
topic | Original Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134722/ https://www.ncbi.nlm.nih.gov/pubmed/37103755 http://dx.doi.org/10.1007/s00415-023-11699-x |
work_keys_str_mv | AT meiselandreas longtermefficacyandsafetyofravulizumabinadultswithantiacetylcholinereceptorantibodypositivegeneralizedmyastheniagravisresultsfromthephase3championmgopenlabelextension AT annanedjillali longtermefficacyandsafetyofravulizumabinadultswithantiacetylcholinereceptorantibodypositivegeneralizedmyastheniagravisresultsfromthephase3championmgopenlabelextension AT vutuan longtermefficacyandsafetyofravulizumabinadultswithantiacetylcholinereceptorantibodypositivegeneralizedmyastheniagravisresultsfromthephase3championmgopenlabelextension AT mantegazzarenato longtermefficacyandsafetyofravulizumabinadultswithantiacetylcholinereceptorantibodypositivegeneralizedmyastheniagravisresultsfromthephase3championmgopenlabelextension AT katsunomasahisa longtermefficacyandsafetyofravulizumabinadultswithantiacetylcholinereceptorantibodypositivegeneralizedmyastheniagravisresultsfromthephase3championmgopenlabelextension AT aguzzirasha longtermefficacyandsafetyofravulizumabinadultswithantiacetylcholinereceptorantibodypositivegeneralizedmyastheniagravisresultsfromthephase3championmgopenlabelextension AT frickglen longtermefficacyandsafetyofravulizumabinadultswithantiacetylcholinereceptorantibodypositivegeneralizedmyastheniagravisresultsfromthephase3championmgopenlabelextension AT gaultlaura longtermefficacyandsafetyofravulizumabinadultswithantiacetylcholinereceptorantibodypositivegeneralizedmyastheniagravisresultsfromthephase3championmgopenlabelextension AT howardjamesf longtermefficacyandsafetyofravulizumabinadultswithantiacetylcholinereceptorantibodypositivegeneralizedmyastheniagravisresultsfromthephase3championmgopenlabelextension AT longtermefficacyandsafetyofravulizumabinadultswithantiacetylcholinereceptorantibodypositivegeneralizedmyastheniagravisresultsfromthephase3championmgopenlabelextension |